- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once - daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, indicated by elevated plasma interleukin-17A (IL-17A) levels, which continued until day 7 for higher doses of ASC50.
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. HONG KONG , Dec. 10, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily oral small molecule fatty acid synthase (FASN) inhibitor for the treatment of moderate-to-severe acne vulgaris, has been accepted by the China National Medical Products Administration (NMPA).
American Century Companies Inc. boosted its stake in Ardmore Shipping Corporation (NYSE: ASC) by 4.4% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 1,642,656 shares of the shipping company's stock after purchasing an additional 69,788 shares during the period. American Century Companies Inc. owned about
- Using Asclet i s' proprietary U ltra- L ong- A cting P latform technology, co-formulation of ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist and ASC35, a once-monthly subcutaneously administered GLP-1R/GIPR dual peptide agonist, demonstrated a comparable pharmacokinetic (PK) profile to ASC36 and ASC35 dosed alone in head-to-head non-human primate studies. - ASC36 monotherapy demonstrated approximately 32 % greater relative body weight reduction compared to eloralintide monotherapy in a head-to-head diet-induced obese (DIO) rat study, while ASC35 monotherapy demonstrated approximately 71% greater relative body weight reduction compared to tirzepatide monotherapy in a head-to-head DIO mouse study.
Ardmore Shipping Corporation ( ASC ) Q3 2025 Earnings Call November 5, 2025 10:00 AM EST Company Participants Gernot Ruppelt - CEO & Director Bart Kelleher - President & Director Conference Call Participants Jonathan Chappell - Evercore ISI Institutional Equities, Research Division Omar Nokta - Jefferies LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Ardmore Shipping's Third Quarter 2025 Earnings Conference Call. Today's call is being recorded, and an audio webcast and presentation are available in the Investor Relations section of the company's website, ardmoreshipping.com.
HAMILTON, Bermuda , Nov. 5, 2025 /PRNewswire/ -- Ardmore Shipping Corporation (NYSE: ASC) ("Ardmore", the "Company" or "we") today announced results for the three and nine months ended September 30, 2025. Highlights and Recent Activity Reported Adjusted earnings of $12.6 million and net income attributable to common stockholders of $12.1 million for the three months ended September 30, 2025, or $0.31 Adjusted earnings per basic and diluted share, compared to Adjusted earnings and net income attributable to common stockholders of $23.3 million, or $0.55 Adjusted earnings per basic and diluted share for the three months ended September 30, 2024.
-Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. -Phase Ib study data of ASC30 subcutaneous (SQ) injection showed that observed half-life reached 46 days for the treatment formulation (Injection A) and 75 days for the maintenance formulation (Injection B).
Ardmore Shipping (NYSE: ASC - Get Free Report) is anticipated to issue its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of $0.28 per share and revenue of $48.3790 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2025 earningoverview page for
-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3 -fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91 % greater relative body weight reduction compared to petrelintide in a head-to-head diet-induced obese ( DIO ) rat study.
DOWNERS GROVE, Ill.--(BUSINESS WIRE)--Duly Health and Care, through its Chicagoland medical group, DuPage Medical Group, Ltd., has announced the acquisition of a minority ownership interest in Valley Ambulatory Surgery Center (Valley ASC) in partnership with Surgery Partners. This collaboration strengthens Duly's commitment to expanding access to high-quality, affordable outpatient surgical care across the Chicagoland area. Valley ASC, located in St. Charles, Illinois, is a respected, multispec.
